Navigation Links
Study Questions Safety of Pneumonia Treatment Guidelines
Date:1/20/2011

WEDNESDAY, Jan. 19 (HealthDay News) -- Intensive care patients who may be infected with strains of pneumonia that are resistant to many drugs may be more likely to die if current treatment guidelines are followed, a new study suggests.

The findings highlight the need to reassess the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) guidelines, said the researchers.

Current guidelines call for immediate antibiotic treatment -- before culture results are known -- of patients at risk for multiple drug-resistant (MDR) infection. The guidelines state that patients should receive a regimen of three antibiotics: two drugs against so-called Gram-negative pathogens and one drug against methicillin-resistant Staphylococcus aureus, or MRSA. The logic in this approach is that at least one drug should be active against any likely infectious agent.

However, several studies conducted since the guidelines were released in 2005 have failed to show that dual Gram-negative therapy is better than treatment with a single drug, the researchers noted.

For their study, a team led by Dr. Daniel Kett, of the University of Miami Miller School of Medicine, enrolled 303 patients at risk for MDR pneumonia from four academic medical centers in the United States. Of those patients, 129 were treated according to the ATS/IDSA guidelines and 174 received a different treatment.

The rate of survival after 28 days was 65 percent in the guidelines-compliant group and 79 percent in the group that didn't adhere to the guidelines, the investigators found.

"Our results further question the need for combination Gram-negative empirical treatment for patients with pneumonia, even those who are severely ill and at risk of multi-drug resistant pathogens," the researchers wrote.

One expert was not surprised by the findings.

"Who gets pneumonia with resistant bacteria? It is a person in such weakened condition that they are vulnerable to pathogens that would otherwise be trivial," noted Dr. Bruce Hirsch, attending physician in the infectious diseases division at North Shore University Hospital in Manhasset, N.Y. "It is a person who has suffered multiple infections already and has been exposed to multiple courses of antibiotics. It is a person with structural lung abnormalities that prevent the lungs from recovering from infections."

According to Hirsch, the new study "demonstrates high mortality rates in patients given recommended antibiotics as well as individualized antibiotics. Even in this age of sophisticated and powerful medications, adherence to the best guidelines can fail us."

For their part, the study authors "recommend that the planned, revised ATS-IDSA guidelines be reassessed before widespread implementation. Since the most common reason for non-compliance was failure to use a secondary anti-Gram-negative drug, we suggest a comparison of regimens employing MRSA treatment and single versus dual Gram-negative coverage."

The study was published in the Jan. 19 online edition of The Lancet Infectious Diseases.

More information

The American Lung Association has more about pneumonia.

-- Robert Preidt

SOURCES: The Lancet Infectious Diseases, news release, Jan. 19, 2011; Bruce Hirsch, M.D., attending physician, infectious diseases division, North Shore University Hospital, Manhasset, N.Y.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Nurses Long Shifts May Put Hospital Patients at Risk: Study
2. Organs From High-Risk Donors Often Shunned, Study Finds
3. 1 in 5 Cancer Survivors Suffers Chronic Pain, Study Finds
4. Pitt study: End-of-life decisions take longer if patient hasnt shared wishes with family
5. New Pediatrics study identifies the risks, consequences of video game addiction
6. Wayne State University study predicts risk of memory loss in healthy, older adults
7. One in 12 Fans Leaves Major Sports Events Drunk: Study
8. Damage of False-Positive Mammograms Overlooked: Study
9. Adult ADHD Often Precedes Certain Type of Dementia: Study
10. Study suggests possible new treatment for severe 2009 H1N1 infection
11. Problem Drinkers Marry Later, Break Up Sooner: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Questions Safety of Pneumonia Treatment Guidelines
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
(Date:4/24/2017)... ... 24, 2017 , ... Ridgecrest Herbals makes it a point to lead the ... waste, and support renewable energy. They believe this is a crucial part of their ... for health issues, and maintain that destroying the environment in the pursuit of profit ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, ... inhabiting the rarified air of pop and film stardom.(1) Not to be left out ... the smile. Grins now run the gamut from being encrusted with jewels and precious ...
(Date:4/24/2017)... Washington (PRWEB) , ... April 24, 2017 , ... Sean ... OptiGrill, Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which ... perhaps any other marketer in the last 25 years. , Now, due to changes ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology: